Xortx announces director resignation

XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU) has announced resignation of a director, effective July 27, 2026. The company has appointed Depesh Narotam as an independent director to fill the vacancy. Mr. Narotam brings over 20 years of experience in the financial services industry, with a focus on debt financing and strategic lending solutions. He has previously held roles at Vancity and Westminster Savings Credit Union (now Prospera Credit Union) and is now Compensation, Governance, and Nominating Committee.

The board of directors confirmed that the resignation occurred without any reservations or reportable events. The company has not disclosed the name of the departing director or specific reasons for the resignation. XORTX emphasized that the change is part of its ongoing governance practices and does not affect the company’s operations or strategic direction.

XORTX continues to focus on its pipeline of therapies targeting progressive kidney disease and gout, including its lead programs XRx-026 and XRx-008. The company remains committed to advancing its clinical development initiatives and improving patient outcomes.